Cadrenal Therapeutics, Inc.CVKD
Price (close)
$1.15
Market cap
$3.6M
P/E
—
Revenue (TTM)
—
Net income
-$11.5M
Dividend yield
—
1-year total return
-91.9%
Net margin
—
Revenue growth
—
Debt / equity
—
What Cadrenal Therapeutics, Inc. does.
for life-threatening immune and thrombotic conditions. As a result of our acquisition of a 12-lipoxygenase (“12-LOX”) platform
of assets in December 2025 (as described in more detail below), we transitioned our primary strategic focus to the development of CAD-1005
for the treatment of immune-mediated and thrombotic disorders. Our lead product candidate, CAD-1005, is a first-in-class selective 12-LOX
Revenue and profit, by fiscal year.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net income | -$6.7M | -$8.4M | -$10.7M | -$13.2M |
| Free cash flow | -$1.2M | -$3.5M | -$7.4M | -$12.6M |
More on CVKD.
- Cadrenal Therapeutics, Inc. summary
- Cadrenal Therapeutics, Inc. financial statements
- Cadrenal Therapeutics, Inc. key metrics
- Cadrenal Therapeutics, Inc. health scores and style box
- Cadrenal Therapeutics, Inc. earnings
- Cadrenal Therapeutics, Inc. dividends
- Cadrenal Therapeutics, Inc. valuation
- Cadrenal Therapeutics, Inc. ownership and insiders
- Cadrenal Therapeutics, Inc. peers
Figures from Cadrenal Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.